Recent advances in atypical antipsychotics

Current Opinion in Investigational Drugs

Volumn 1, Issue 4, 2000, Pages 481-493

  Armer, R ^a   Miller, D J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

AMPA receptor; Antipsychotic; Dopamine receptor; Glutamate receptor; NMDA receptor

Indexed keywords

1 [2 [4 (6 FLUORO 1,2 BENZISOXAZOL 3 YL) 1 PIPERIDYL]ETHYL] 3 PHENYL 2 IMIDAZOLINONE; 1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMPA RECEPTOR; ARIPIPRAZOLE; BLONANSERIN; BW 737C89; CEE 03 310; CEE 03 320; CLOZAPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; ECOPIPAM; GLUTAMATE RECEPTOR; HALOPERIDOL; ILOPERIDONE; LU 201640; LY 270411; MAZAPERTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULFONAMIDE; TALIPEXOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGRANULOCYTOSIS; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOPAMINERGIC TRANSMISSION; DRUG COST; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SCHIZOPHRENIA; SUSTAINED RELEASE FORMULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 0034537379     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Recent advances in potential atypical antipsychotics: Past, present and future hopes - Preclinical and clinical considerations
2. Potential therapeutic targets for schizophrenia
3. Recent advances in novel atypical antipsychotic agents: Potential therapeutic agents for the treatment of schizophrenia
4. Use atypicals first for schizophrenia
5. The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999
6. Role of atypical antipsychotic polypharmacotherapy in the treatment of schizophrenia
7. Olanzapine or clozapine for resistant schizophrenia
8. Myocarditis and cardiomyopathy associated with clozapine
9. Current problems in pharmacovigilance
10. Digital Gene Technologies and the Mental Health Research Institute of Victoria, Australia, to study clozapine-induced agranulocytosis in the treatment of schizophrenia
11. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control
12. Clinical improvement and tolerability is maintained long term in elderly patients with psychotic disorders treated with Seroquel® (quetiapine)
13. Seroquel® (quetiapine fumerate), a novel antipsychotic: Experience in elderly patients with psychotic disorders
14. Effects of Seroquel® (quetiapine) on reducing hostility and psychosis in patients with Alzheimer's disease
15. Seroquel® (quetiapine) improves psychotic symptoms associated with Parkinson's disease
16. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
17. Efficacy and tolerability of 'Seroquel' compared with haloperidol in schizophrenia patients partially responsive to conventional antipsychotic treatment
18. Changes in cognitive function with quetiapine (Seroquel) versus haloperidol
19. Management of weight gain and diabetes by clozapine-seroquel combination therapy: Preliminary findings
20. Seroquel® in the treatment of neuroleptic dependent serious mood disorders
21. Quetiapine in psychotic depression
22. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
23. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder
24. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium
25. CX-516
26. Synergistic interactions between AMPAkines and antipsychotic drugs
27. Monaminergic synapses and schizophrenia: 45 years of neuroleptics
28. Mechanism of action of antipsychotic drugs
29. Beyond the dopamine receptor: The DARPP32/protein phosphatase-1 cascade
30. 1 receptor antagonists in rodents, in primates and in humans
31. 2 receptor antagonist, on Fos protein expression in the rat forebrain
32. Clinical effects of perospirone on schizophrenia: A double-blind study with haloperidol
33. Unique pharmacological profile of a novel antipsychotic drug, aripiprazole (OPC-14597)
34. 1A-adrenergic affinity and a low potential for extrapyramidal side effects
35. Biotransformation of the antipsychotic agent, mazapertine, in dog - mass spectral characterisation and identification of metabolites
36. RWJ-37796
37. The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl) aklyl]pyridines. Dopamine auto-receptor agonists and potential antipsychotic agents
38. Identification, characterisation and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1-yl) methyl]pyridine (Cl-1007), a dopamine autoreceptor agonist and potential antipsychotic agent
39. 3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics
40. 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia
41. 4 receptors: Basic and clinical status
42. Pharmacia and Upjohn
43. (S)-(-)-4-[4-[2-(Isochroman-2-yl)ethyl]-piperazin-1-yl]benzene-sulfonamid e, a selective dopamine D(4) antagonist
44. (+)-LU-111995
45. 4 and 5-hydroxytripamine 2A antagonist: Pharmacological characterisation and first clinical experience
46. Electrophysiological effects of LU111995 on canine hearts: In vivo and in vitro studies
47. 2 template
48. 4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests
49. 4 dopamine receptor antagonist (L-745-870) in acutely psychotic inpatients with schizophrenia
50. 4 receptor
51. 2 Antagonists: A concept for the design of schizophrenia
52. E-5842: Antipsychotic sigma ligand
53. 6 receptor antagonist
54. Famotidine in the management of schizophrenia
55. Glutamatergic aspects of schizophrenia
56. Glutamate and related acidic excitatory neurotransmitters: From basic science to clinical application
57. Inhibitors of mammalian central nervous system selective amino acid transporters
58. A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system
59. Modulation of N-methyl-D-aspartate receptor function by glycine transport
60. Metabotropic G-protein-coupled glutamate receptors as therapeutic targets
61. Glutamate and schizophrenia
62. Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties
63. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats
64. Synthesis, pharmacological characterization, and molecular modelling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systematically active agonists for group II metabotropic glutamate receptors
65. Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenyl-alkylamine sigma ligands as potential antipsychotic drugs
66. Synthesis and SAR of 1-alkyl-2-phenylethylamine derivatives designed from N,N-dipropyl-4-methoxy-3-(2-phenylethoxy)phenyl-ethylamine to discover sigma-1 ligands
67. Repeated administration of the neurotensin antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems
68. Cholecystokinin CCK-B receptor mRNA isoforms: Expression in schizophrenic brains
69. The role of nicotine and nicotine receptors in psychopathology
70. 2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists
71. Critical review of GABA-ergic drugs in the treatment of schizophrenia
72. Three independent lines of evidence suggest retinoids as causal to schizophrenia